Karyopharm Therapeutics Inc. (KPTI)

Price$9.08

Value ScoreB

Growth ScoreC

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)53.64%

Price vs S&P 500 (4W)5.10%

VGM Score62.13

Market Capitalization$205.78M

All Metrics

Book Value / Share (Quarterly)$0.68

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-2.40%

Cash Flow / Share (Quarterly)$-2.62

Price vs S&P 500 (YTD)15.21%

Gross Margin (TTM)96.03%

Net Profit Margin (TTM)-129.02%

EPS (TTM)$-14.84

10-Day Avg Trading Volume0.39M

EPS Excl Extra (TTM)$-14.84

Revenue Growth (5Y)6.21%

EPS (Annual)$-17.93

ROI (Annual)-81.28%

Gross Margin (Annual)95.93%

Net Profit Margin (5Y Avg)-89.84%

Cash / Share (Quarterly)$4.03

Revenue Growth QoQ (YoY)16.83%

ROA (Last FY)-180.82%

Revenue Growth TTM (YoY)6.33%

EBITD / Share (TTM)$-10.22

ROE (5Y Avg)-210.81%

Operating Margin (TTM)-96.99%

Cash Flow / Share (Annual)$-4.12

P/B Ratio4.07x

P/B Ratio (Quarterly)22.52x

Net Income / Employee (Annual)$-859,800

EV / Revenue (TTM)2.72x

Net Interest Coverage (TTM)-3.55x

ROA (TTM)-176.87%

EPS Incl Extra (Annual)$-17.93

Current Ratio (Annual)1.12x

Quick Ratio (Quarterly)0.97x

3-Month Avg Trading Volume0.83M

52-Week Price Return113.15%

Revenue / Employee (TTM)$662,800

Tangible BV / Share (Quarterly)$-0.88

P/S Ratio (Annual)1.41x

Asset Turnover (Annual)1.35x

52-Week High$10.99

Operating Margin (5Y Avg)-76.47%

EPS Excl Extra (Annual)$-17.93

CapEx CAGR (5Y)-7.53%

26-Week Price Return61.57%

Quick Ratio (Annual)0.98x

13-Week Price Return2.95%

Total Debt / Equity (Annual)3.78x

Current Ratio (Quarterly)1.08x

Enterprise Value$411.66M

Revenue / Share Growth (5Y)54.83%

Asset Turnover (TTM)1.37x

Book Value / Share Growth (5Y)-34.14%

Revenue / Employee (Annual)$640,600

Inventory Turnover (Annual)1.36x

Pretax Margin (Annual)-134.18%

Cash / Share (Annual)$3.48

3-Month Return Std Dev91.04%

Gross Margin (5Y Avg)96.70%

Net Income / Employee (TTM)$-855,100

ROE (Last FY)-388.71%

Net Interest Coverage (Annual)-3.32x

EPS Basic Excl Extra (Annual)$-17.93

Receivables Turnover (TTM)5.16x

Total Debt / Equity (Quarterly)3.78x

EPS Incl Extra (TTM)$-14.84

Receivables Turnover (Annual)5.13x

ROI (TTM)-66.32%

P/S Ratio (TTM)1.36x

Pretax Margin (5Y Avg)-89.70%

Revenue / Share (Annual)$13.36

Tangible BV / Share (Annual)$-0.15

Price vs S&P 500 (52W)88.78%

Year-to-Date Return23.37%

5-Day Price Return-7.54%

EPS Normalized (Annual)$-17.93

ROA (5Y Avg)-74.72%

Net Profit Margin (Annual)-134.21%

Month-to-Date Return-0.22%

Cash Flow / Share (TTM)$-1.29

EBITD / Share (Annual)$-13.97

Operating Margin (Annual)-104.80%

LT Debt / Equity (Annual)3.78x

ROI (5Y Avg)-79.29%

LT Debt / Equity (Quarterly)3.78x

EPS Basic Excl Extra (TTM)$-14.84

P/B Ratio (Annual)22.52x

Inventory Turnover (TTM)1.43x

Pretax Margin (TTM)-129.01%

Book Value / Share (Annual)$0.68

Price vs S&P 500 (13W)-5.31%

Beta0.83x

Revenue / Share (TTM)$6.86

ROE (TTM)-182.43%

52-Week Low$3.65

vGradeB

gGradeC

mGradeB

vgmGradeB

Show chart for

Earnings Surprise History

Q1 26-1.02est. -1.46

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.15

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
KPTIKaryopharm Therapeutics Inc.	B	C	B	$9.08
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Karyopharm Therapeutics is a commercial-stage pharmaceutical company specializing in cancer drugs that inhibit nuclear export. The company's lead product, XPOVIO (selinexor), targets exportin 1 (XPO1), preventing the transport of cancer-promoting proteins out of the cell nucleus. This mechanism represents a novel approach to disrupting cancer cell survival.